Cargando…

Aging‐related hyperphosphatemia impairs myogenic differentiation and enhances fibrosis in skeletal muscle

BACKGROUND: Hyperphosphatemia has been related to the development of sarcopenia in aging mice. We describe the intracellular mechanisms involved in the impairment of the myogenic differentiation promoted by hyperphosphatemia and analyse these mechanisms in the muscle from older mice. METHODS: C(2)C(...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sosa, Patricia, Alcalde‐Estévez, Elena, Asenjo‐Bueno, Ana, Plaza, Patricia, Carrillo‐López, Natalia, Olmos, Gemma, López‐Ongil, Susana, Ruiz‐Torres, María Piedad
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8517361/ https://www.ncbi.nlm.nih.gov/pubmed/34337906 http://dx.doi.org/10.1002/jcsm.12750

Ejemplares similares

Hyperphosphatemia-Induced Oxidant/Antioxidant Imbalance Impairs Vascular Relaxation and Induces Inflammation and Fibrosis in Old Mice
por: Asenjo-Bueno, Ana, et al.
Publicado: (2021)

Uraemic toxins impair skeletal muscle regeneration by inhibiting myoblast proliferation, reducing myogenic differentiation, and promoting muscular fibrosis
por: Alcalde-Estévez, Elena, et al.
Publicado: (2021)

Endothelin-1 induces cellular senescence and fibrosis in cultured myoblasts. A potential mechanism of aging-related sarcopenia
por: Alcalde-Estévez, Elena, et al.
Publicado: (2020)

Hyperphosphatemia induces senescence in human endothelial cells by increasing endothelin‐1 production
por: Olmos, Gemma, et al.
Publicado: (2017)

Hyperphosphatemia Promotes Senescence of Myoblasts by Impairing Autophagy Through Ilk Overexpression, A Possible Mechanism Involved in Sarcopenia
por: Sosa, Patricia, et al.
Publicado: (2018)

Dietary phosphate restriction prevents the appearance of sarcopenia signs in old mice
por: Alcalde‐Estévez, Elena, et al.
Publicado: (2023)

Corrigendum to “Glucose Oxidase Induces Cellular Senescence in Immortal Renal Cells through ILK by Downregulating Klotho Gene Expression”
por: Troyano-Suárez, Nuria, et al.
Publicado: (2016)

Glucose Oxidase Induces Cellular Senescence in Immortal Renal Cells through ILK by Downregulating Klotho Gene Expression
por: Troyano-Suárez, Nuria, et al.
Publicado: (2015)

Vitamin D Treatment Prevents Uremia-Induced Reductions in Aortic microRNA-145 Attenuating Osteogenic Differentiation despite Hyperphosphatemia
por: Carrillo-López, Natalia, et al.
Publicado: (2022)

Hyperphosphatemia and Cardiovascular Disease
por: Zhou, Chao, et al.
Publicado: (2021)

Nutritional Guideline for the Management of Mexican Patients with CKD and Hyperphosphatemia
por: Palafox-Serdán, Frida, et al.
Publicado: (2020)

Effect of Intradialytic Exercise on Hyperphosphatemia and Malnutrition
por: Salhab, Nada, et al.
Publicado: (2019)

Control of hyperphosphatemia and maintenance of calcemia in CKD
por: Carvalho, Aluizio Barbosa, et al.
Publicado: (2021)

Phosphate intake, hyperphosphatemia, and kidney function
por: Rubio-Aliaga, Isabel, et al.
Publicado: (2022)

Hyperphosphatemia increases inflammation to exacerbate anemia and skeletal muscle wasting independently of FGF23-FGFR4 signaling
por: Czaya, Brian, et al.
Publicado: (2022)

Use of Nicotinamide to Treat Hyperphosphatemia in Dialysis Patients
por: Lenglet, Aurélie, et al.
Publicado: (2013)

Hyperphosphatemia: The hidden killer in chronic kidney disease
por: Askar, Akram M.
Publicado: (2015)

Tumor lysis syndrome with massive hyperphosphatemia and hyperuricemia
por: Koratala, Abhilash
Publicado: (2017)

Hyperphosphatemia is associated with high mortality in severe burns
por: Kuo, George, et al.
Publicado: (2018)

Uremic Tumoral Calcinosis Resolved by Improvements in Hyperphosphatemia
por: Watanabe, Hirofumi, et al.
Publicado: (2017)

Hyperphosphatemia Management in Patients with Chronic Kidney Disease
por: Shaman, Ahmed M., et al.
Publicado: (2016)

Non-occlusive Mesenteric Ischemia with Significant Hyperphosphatemia
por: Yamada, Aki, et al.
Publicado: (2022)

Myogenic specification of side population cells in skeletal muscle
por: Asakura, Atsushi, et al.
Publicado: (2002)

Myogenic Differentiation of Stem Cells for Skeletal Muscle Regeneration
por: Yu, Dengjie, et al.
Publicado: (2021)

A Case of Hyperphosphatemia and Elevated Fibroblast Growth Factor 23: A Brief Review of Hyperphosphatemia and Fibroblast Growth Factor 23 Pathway
por: Wang, Joseph, et al.
Publicado: (2017)

Safety and efficacy of nicotinamide in the management of hyperphosphatemia in patients on hemodialysis
por: Vasantha, J., et al.
Publicado: (2011)

NPT-IIb Inhibition Does Not Improve Hyperphosphatemia in CKD
por: Larsson, Tobias E., et al.
Publicado: (2017)

Npt2a as a target for treating hyperphosphatemia
por: Thomas, Linto, et al.
Publicado: (2022)

Phosphate-Trapping Liposomes for Long-Term Management of Hyperphosphatemia
por: Tzror-Azankot, Chen, et al.
Publicado: (2022)

FRI699 Hyperphosphatemia In The Setting Of Sodium Hypochlorite Use
por: Champagne, Kareen, et al.
Publicado: (2023)

The myogenic kinome: protein kinases critical to mammalian skeletal myogenesis
por: Knight, James DR, et al.
Publicado: (2011)

Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle
por: Boyer, Olivier, et al.
Publicado: (2021)

Bioactive nanoglass regulating the myogenic differentiation and skeletal muscle regeneration
por: Winston, Dagogo Dorothy, et al.
Publicado: (2023)

Impaired erythropoietin synthesis in chronic kidney disease is caused by alterations in extracellular matrix composition
por: Olmos, Gemma, et al.
Publicado: (2017)

Phosphate stimulates myotube atrophy through autophagy activation: evidence of hyperphosphatemia contributing to skeletal muscle wasting in chronic kidney disease
por: Zhang, Yue-yue, et al.
Publicado: (2018)

The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients
por: Shigematsu, Takashi, et al.
Publicado: (2012)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Multidisciplinary Perspectives of Current Approaches and Clinical Gaps in the Management of Hyperphosphatemia
por: Vallée, Michel, et al.
Publicado: (2021)

Tmem174, a regulator of phosphate transporter prevents hyperphosphatemia
por: Sasaki, Sumire, et al.
Publicado: (2022)

Sucroferric oxyhydroxide for hyperphosphatemia: a review of real-world evidence
por: Coyne, Daniel W., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1pnrj06v5fqnhj1ubouc4j6nhd